Decoy Therapeutics (DCOY) Share-based Compensation (2015 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Share-based Compensation of $900000.0 for Q1 2026, up 2583.84% year-over-year from $33534.0 in Q1 2025, and up 545.05% quarter-over-quarter from $139523.0 in Q4 2025.
Decoy Therapeutics (DCOY) Share-based Compensation (2015 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Share-based Compensation for 12 consecutive years, with $900000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 2583.84% year-over-year to $900000.0; the TTM figure through Mar 2026 stood at $900000.0 (up 291.72% YoY), while the FY2025 annual figure was $1.1 million, up 301.86% from the prior year.
- Share-based Compensation climbed to $900000.0 in Q1 2026 per DCOY's latest filing, from $139523.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $900000.0 in Q1 2026 and bottomed at -$25531.0 in Q3 2022.
- Historically, Share-based Compensation has averaged $150345.4 across 5 years, with a median of $81338.0 in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 106.18% — and 2026, when it soared 2583.84%.
- Decoy Therapeutics' Share-based Compensation stood at -$25531.0 in 2022, then soared by 434.4% to $85376.0 in 2023, then sank by 40.21% to $51045.0 in 2024, then surged by 173.33% to $139523.0 in 2025, then jumped by 545.05% to $900000.0 in 2026.
- Business Quant data shows DCOY's Share-based Compensation at $900000.0 in Q1 2026, $139523.0 in Q4 2025, and $22846.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Decoy Therapeutics | 1.82 Mn | 1.82 Mn | - | 700,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 700,000.00 |
| Jun 30, 2026 | 700,000.00 |
| Mar 31, 2026 | 900,000.00 |
| Mar 31, 2026 | 900,000.00 |
| Dec 31, 2025 | 139,523.00 |
| Dec 31, 2025 | 139,523.00 |
| Sep 30, 2025 | 22,846.00 |
| Sep 30, 2025 | 22,846.00 |
| Jun 30, 2025 | 23,155.00 |
| Jun 30, 2025 | 23,155.00 |
| Mar 31, 2025 | 33,534.00 |
| Mar 31, 2025 | 33,534.00 |
| Dec 31, 2024 | 51,045.00 |
| Dec 31, 2024 | 51,045.00 |
| Sep 30, 2024 | 60,009.00 |
| Sep 30, 2024 | 60,009.00 |
| Jun 30, 2024 | 85,168.00 |
| Jun 30, 2024 | 85,168.00 |
| Mar 31, 2024 | 77,508.00 |
| Mar 31, 2024 | 77,508.00 |